IP Library Granted Patent US 8,685,980
Granted Patent B2
US 8,685,980 · App. 13/060,154 · Granted Apr 1, 2014

Pyrrolopyrimidine compounds and their uses

Inventors: Gilbert Ebai Besong (Bad Duerkheim, DE); Christopher Thomas Brain (North Reading, MA); Clinton Alan Brooks (Smyrna, GA); Miles Stuart Congreve (Royston, GB); Claudio Dagostin (Cambridge, GB); Guo He (Lexington, MA); Ying Hou (Belmont, MA); Steven Howard (Cambridge, GB); Yue Li (Shanghai, CN); Yipin Lu (Dublin, CA); Paul Neil Mortenson (Cambridge, GB); Troy D. Smith (Nashua, NH); Moo Je Sung (Belmont, MA); Steven John Woodhead (San Diego, CA); Wojciech Wrona (Waltham, MA); Bharat Lagu (Acton, MA)
Assignees: Novartis AG; Astex Therapeutics, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,980
App. No.
13/060,154
Granted
Apr 1, 2014
Kind
B2
Abstract

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Claims (88)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein

X is CR 9 ;

R 1 is CONR 5 R 6 , and R 5 and R 6 are C 1-8 alkyl;

R 2 is C 3-14 cycloalkyl;

L is a bond, C 1-8 alkylene, C(O), or C(O)NH, and wherein L may be substituted or unsubstituted;

Y is H, R 11 , NR 12 R 13 , OH, or Y is part of the following group

where Y is CR 9 or N;

where 0-3 R 8 may be present, and R 8 is C 1-8 alkyl, oxo, halogen, or two or more R 8 may form a bridged alkyl group;

W is CR 9 , or N;

R 3 is H, C 1-8 alkyl, C 1-8 alkylR 14 , C 3-14 cycloalkyl, C(O)C 1-8 alkyl, C 1-8 haloalkyl, C 1-8 alkylOH, C(O)NR 14 R 15 , C 1-8 cyanoalkyl, C(O)R 14 , C 0-8 alkylC(O)C 0-8 alkylNR 14 R 15 , C 0-8 alkylC(O)OR 14 , NR 14 R 15 , SO 2 C 1-8 alkyl, C 1-8 alkylC 3-14 cycloalkyl, C(O)C 1-8 alkylC 3-14 cycloalkyl, C 1-8 alkoxy, or OH which may be substituted or unsubstituted when R 3 is not H;

R 9 is H or halogen;

R 11 , R 12 , R 13 , R 14 , and R 15 are each independently selected from H, C 1-8 alkyl, C 3-14 cycloalkyl, a 3-14 membered cycloheteroalkyl group, a C 6-14 aryl group, a 5-14 membered heteroaryl group, alkoxy, C(O)H, C(NH)OH, C(NH)OCH 3 , C(O)C 1-3 alkyl, C 1-8 alkylNH 2 , and C 1-6 alkylOH, and wherein R 11 , R 12 , and R 13 , R 14 , and R 15 when not H may be substituted or unsubstituted;

m and n are independently 0-2; and

wherein L, R 3 , R 11 , R 12 , and R 13 , R 14 , and R 15 may be substituted with one or more of C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-14 cycloalkyl, 5-14 membered heteroaryl group, C 6-14 aryl group, a 3-14 membered cycloheteroalkyl group, OH, (O), CN, alkoxy, halogen, or NH 2 .

2. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1 wherein R 3 is H, C 1-8 alkyl, C 3-14 cycloalkyl, C(O)C 1-8 alkyl, C 1-8 alkylOH, C 1-8 cyanoalkyl, C 0-8 alkylC(O)C 0-8 alkylNR 14 R 15 , C 0-8 alkylC(O)OR 14 , NR 14 R 15 , C 1-8 alkylC 3-14 cycloalkyl, C(O)C 1-8 alkylC 3-14 cycloalkyl, C 1-8 alkylR 14 , C 1-8 haloalkyl, or C(O)R 14 , which may be substituted with one or more of OH, CN, F, or NH 2 , and wherein R 14 and R 15 are each independently selected from H, C 1-8 alkyl, C 3-14 cycloalkyl, alkoxy, C(O)C 1-3 alkyl, C 1-8 alkylNH 2 , or C 1-6 alkylOH.

3. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1 wherein R 3 is H, C 1-8 alkyl, or C 1-8 alkylOH.

4. The compound of formula I or a pharmaceutically acceptable salt thereof according claim 1 wherein Y is H, OH, or Y is part of the following group

, where Y is N and W is CR 9 , or N;

where 0-2 R 8 may be present, and R 8 is C 1-8 alkyl, oxo, or two or more R 8 may form a bridged alkyl group.

5. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1 wherein R 2 is cyclopentane.

6. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1 wherein Y is

where m and n are 1, and Y and W are N.

7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

8. A compound of formula I(a):

I(a)

or a pharmaceutically acceptable salt thereof, wherein:

R 50 is CONR 54 R 55 ;

R 51 is C 3-14 cycloalkyl which may be unsubstituted or substituted by C 1-3 alkyl, or OH;

Z is CH or N; and

V is NR 56 or CHR 57 ;

R 54 and R 55 are both methyl; and

R 52 , R 53 R 56 , and R 57 are H.

9. A compound selected from:

7-Cyclopentyl-2-{5-[4-(2-fluoro-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-(4-dimethylamino-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-6′-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

2-[5-(4-Carbamoylmethyl-piperazin-1-yl)-pyridin-2-ylamino]-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

2-{5-[4-(2-Amino-acetyl)-piperazin-1-yl]-pyridin-2-ylamino}-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

2-[5-(3-Amino-pyrrolidin-1-yl)-pyridin-2-ylamino]-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-methoxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[4-(2-hydroxyethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyrazinyl-5′-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-((R)-3-methyl-piperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-((S)-3-methylpiperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(3-methylpiperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(3-hydroxypropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(pyrrolidine-1-carbonyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-((S)-2,3-dihydroxypropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-(5-{4-[2-(2-hydroxyethoxy)-ethyl]-piperazin-1-yl}-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-hydroxy-1-methylethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{6-[4-(2-hydroxyethyl)-piperazin-1-yl]-pyridazin-3-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2,3-dihydroxypropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-((R)-2,3-dihydroxypropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-(3,4,5,6-tetrahydro-2H-[1,2′]bipyrazinyl-5′-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(piperazine-1-carbonyl)-pyridin-2-ylamino]-7H-pyrrolo[2,3d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(4-dimethylaminopiperidine-1-carbonyl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-(1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-6-ylamino)-7H-pyrrolo[2,3d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-((S)-3-methylpiperazin-1-ylmethyl)-pyridin-2-ylamino]-7Hpyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-((S)-2-hydroxypropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-((R)-2-hydroxypropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(4-isopropyl-piperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(4-isopropyl-piperazine-1-carbonyl)-pyridin-2-ylamino-1-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(4-methyl-pentyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-hydroxy-2methylpropyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(3,3-dimethyl-piperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(3,8-diaza-bicyclo[3.2.4]oct-3-ylmethyl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(4-ethyl-piperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(4-cyclopentyl-piperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-(1′-isopropyl-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[(R)-4-(2-hydroxyethyl)-3-methyl-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[(S)-4-(2-hydroxyethyl)-3-methyl-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-hydroxyethyl)-piperazin-1-ylmethyl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-dimethylaminoacetyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-ethyl-butyl)piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

2-{5-[4-(2-Cyclohexyl-acetyl)piperazin-1-yl]-pyridin-2-ylamino}-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(3-cyclopentyl-propionyl)-piperazin-1-yl]-pyridin-2-ylamino}7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-[5-(4-isobutylpiperazin-1-yl)-pyridin-2-ylamino]-7H-pyrrolo[2,3d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-isopropoxyethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7Hpyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

7-Cyclopentyl-2-{5-[4-(2-methyl-butyl)piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; and

7-Cyclopentyl-2-[1′-(2-hydroxy-ethyl)-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-6-ylamino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide;

or a pharmaceutically acceptable salt thereof.

10. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 3 wherein R 3 is H, methyl, ethyl, propyl, isopropyl, CH 2 OH, or CH 2 CH 2 OH.

11. The compound or a pharmaceutically acceptable salt thereof according to claim 1 wherein m is 2 and n is 1.

12. The compound or a pharmaceutically acceptable salt thereof according to claim 1 wherein R 8 is methyl, ethyl, propyl, butyl, oxo, or two R 8 can form a bridged group.

13. The compound according to claim 1 wherein L is a bond an Y is not H; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 wherein L is a bond and Y is

where m and n are 1 or 2, and Y and W are N; or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 14 wherein R 3 is H, methyl, ethyl, propyl, or isopropyl, or CH 2 OH, or CH 2 CH 2 OH; or a pharmaceutically acceptable salt thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2021
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 056549/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: ASTEX THERAPEUTICS LIMITED; NOVARTIS AG
To: ASTEX THERAPEUTICS LIMITED; NOVARTIS AG
Reel/Frame 039149/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2012
From: LAGU, BHARAT
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 029164/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2012
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 029164/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2011
From: BRAIN, CHRISTOPHER THOMAS; BROOKS, CLINTON A.; HE, GUO; HOU, YING; LI, YUE; LU, YIPIN; SMITH, TROY; SUNG, MOO JE; WRONA, WOJCIECH
To: NOVARTIS AG
Reel/Frame 025847/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2011
From: BESONG, GILBERT; CONGREVE, MILES STUART; DAGOSTIN, CLAUDIO; HOWARD, STEVEN; MORTENSON, PAUL; WOODHEAD, STEVEN
To: ASTEX THERAPEUTICS, LTD.
Reel/Frame 025849/0141 →
Continuity (2)
Provisional Application 61091037 · Aug 22, 2008
Related Publication 20110152244A1 · Jun 23, 2011